TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and GoalsFrancesco Manfredi, Eliana Ruggiero|Frontiers in Immunology|2020Cited by 101
TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strengthMartina Spiga, Neda Mohammadi, Laura Perani et al.|Nature Communications|2026Cited by 2
Abstract 5: Cytosine base editor ameliorates the safety profile of TCR edited T cells for the adoptive cell therapy of gastrointestinal tumorsMartina Spiga, Chiara Bonini, Alessia Potenza et al.|Cancer Research|2024Cited by 0
Abstract LB029: TIGIT deletion rescues the antitumor activity of low avidity T cells by increasing TCR signal strengthMartina Spiga, Chiara Bonini, Alessia Potenza et al.|Cancer Research|2025Cited by 0